🚀 VC round data is live in beta, check it out!
Zomedica Valuation Multiples
Discover revenue and EBITDA valuation multiples for Zomedica and similar public comparables like Cognition Therapeutics, Cassava Sciences, Vistin Pharma, Sedana Medical and more.
Zomedica Overview
About Zomedica
Zomedica Corp is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. The company's product portfolio includes diagnostics and therapeutics that emphasize patient health and practice health. The company is focused on the final development and commercialization of its TRUFORMA platform, which detects thyroid disorders in dogs & cats and adrenal disorders in dogs. Its operations are comprised of two reportable segments namely Diagnostic and Therapeutic Devices. It earns the majority of revenue from the therapeutics segment.
Founded
2013
HQ
Employees
152
Website
Financials (LTM)
EV
$55M
Zomedica Financials
Zomedica reported last 12-month revenue of $32M.
In the same LTM period, Zomedica generated had net loss of ($82M).
Revenue (LTM)
Zomedica P&L
In the most recent fiscal year, Zomedica reported revenue of $32M and EBITDA of ($21M).
Zomedica expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $32M | XXX | $32M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $22M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 68% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($21M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (64%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (89%) | XXX | XXX | XXX |
| Net Profit | ($82M) | XXX | ($82M) | XXX | XXX | XXX |
| Net Margin | (256%) | XXX | (256%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Zomedica Stock Performance
Zomedica has current market cap of $106M, and enterprise value of $55M.
Market Cap Evolution
Zomedica's stock price is $0.11.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $55M | $106M | 0.0% | XXX | XXX | XXX | $-0.08 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialZomedica Valuation Multiples
Zomedica trades at 1.7x EV/Revenue multiple, and (2.7x) EV/EBITDA.
EV / Revenue (LTM)
Zomedica Financial Valuation Multiples
As of April 20, 2026, Zomedica has market cap of $106M and EV of $55M.
Equity research analysts estimate Zomedica's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Zomedica has a P/E ratio of (1.3x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $106M | XXX | $106M | XXX | XXX | XXX |
| EV (current) | $55M | XXX | $55M | XXX | XXX | XXX |
| EV/Revenue | 1.7x | XXX | 1.7x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (2.7x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (1.9x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 2.5x | XXX | XXX | XXX |
| P/E | (1.3x) | XXX | (1.3x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (3.0x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Zomedica Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Zomedica Margins & Growth Rates
Zomedica's revenue in the last fiscal year grew by 17%.
Zomedica's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.3M for the same period.
Zomedica Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 17% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (64%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (48%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 58% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 76% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 22% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 157% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Zomedica Public Comps
See public comps and valuation multiples for other Biopharmaceuticals and Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Zomedica | XXX | XXX | XXX | XXX | XXX | XXX |
| Cognition Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cassava Sciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Vistin Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Sedana Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| Darya-Varia Laboratoria | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Zomedica M&A Activity
Zomedica acquired XXX companies to date.
Last acquisition by Zomedica was on XXXXXXXX, XXXXX. Zomedica acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Zomedica
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialZomedica Investment Activity
Zomedica invested in XXX companies to date.
Zomedica made its latest investment on XXXXXXXX, XXXXX. Zomedica invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Zomedica
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Zomedica
| When was Zomedica founded? | Zomedica was founded in 2013. |
| Where is Zomedica headquartered? | Zomedica is headquartered in United States. |
| How many employees does Zomedica have? | As of today, Zomedica has over 152 employees. |
| Who is the CEO of Zomedica? | Zomedica's CEO is Larry Heaton. |
| Is Zomedica publicly listed? | Yes, Zomedica is a public company listed on OTC Pink Sheets. |
| What is the stock symbol of Zomedica? | Zomedica trades under ZOMDF ticker. |
| When did Zomedica go public? | Zomedica went public in 2016. |
| Who are competitors of Zomedica? | Zomedica main competitors are Cognition Therapeutics, Cassava Sciences, Vistin Pharma, Sedana Medical. |
| What is the current market cap of Zomedica? | Zomedica's current market cap is $106M. |
| What is the current revenue of Zomedica? | Zomedica's last 12 months revenue is $32M. |
| What is the current EV/Revenue multiple of Zomedica? | Current revenue multiple of Zomedica is 1.7x. |
| Is Zomedica profitable? | No, Zomedica is not profitable. |
| What is the current net income of Zomedica? | Zomedica's last 12 months net income is ($82M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.